APA-viite (7. p.)
Xiaoxing, G., Xu, Y., Liu, A., Yang, X., Chen, W., Junzhen, G., . . . Mengzhao, W. (Nov 2025). 1060 Updated results from a multicenter, randomized phase 2 trial: Ruxolitinib added to corticosteroids for severe checkpoint inhibitor-associated pneumonitis. Journal for Immunotherapy of Cancer. https://doi.org/10.1136/jitc-2025-SITC2025.1060
Chicago-viite (17. p.)
Xiaoxing, Gao, et al. "1060 Updated Results from a Multicenter, Randomized Phase 2 Trial: Ruxolitinib Added to Corticosteroids for Severe Checkpoint Inhibitor-associated Pneumonitis." Journal for Immunotherapy of Cancer Nov 2025. https://doi.org/10.1136/jitc-2025-SITC2025.1060.
MLA-viite (9. p.)
Xiaoxing, Gao, et al. "1060 Updated Results from a Multicenter, Randomized Phase 2 Trial: Ruxolitinib Added to Corticosteroids for Severe Checkpoint Inhibitor-associated Pneumonitis." Journal for Immunotherapy of Cancer, Nov 2025, https://doi.org/10.1136/jitc-2025-SITC2025.1060.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.